Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Covington
Johnson and Johnson
Queensland Health
McKinsey
Citi

Generated: July 20, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,933,030

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,933,030 protect, and when does it expire?

Patent 8,933,030 protects LINZESS and is included in one NDA.

This patent has fourteen patent family members in eleven countries.

Summary for Patent: 8,933,030
Title:Treatments for gastrointestinal disorders
Abstract: The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein, using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
Inventor(s): Fretzen; Angelika (Somerville, MA), Zhao; Hong (Lexington, MA), Kessler; Marco (Danvers, MA)
Assignee: Ironwwod Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:13/579,685
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,933,030
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 8,933,030
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 8,933,030

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan Sales Llc LINZESS linaclotide CAPSULE;ORAL 202811-003 Jan 25, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS. ➤ Try a Free Trial
Allergan Sales Llc LINZESS linaclotide CAPSULE;ORAL 202811-001 Aug 30, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Allergan Sales Llc LINZESS linaclotide CAPSULE;ORAL 202811-002 Aug 30, 2012 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,933,030

PCT Information
PCT FiledFebruary 17, 2011PCT Application Number:PCT/US2011/025274
PCT Publication Date:August 25, 2011PCT Publication Number: WO2011/103311

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Boehringer Ingelheim
Cantor Fitzgerald
Daiichi Sankyo
Deloitte
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.